PURE Bioscience, Inc. (PURE)
OTCMKTS
· Delayed Price · Currency is USD
0.0800
+0.0100 (14.29%)
Jan 17, 2025, 4:00 PM EST
PURE Bioscience Income Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Oct '24 Oct 31, 2024 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 | 2019 - 2015 |
| Revenue | 1.8 | 1.96 | 1.88 | 1.85 | 3.93 | 6.92 | Upgrade
|
| Revenue Growth (YoY) | -15.55% | 4.58% | 1.30% | -52.81% | -43.23% | 262.34% | Upgrade
|
| Cost of Revenue | 0.76 | 0.81 | 0.91 | 0.85 | 1.85 | 2.9 | Upgrade
|
| Gross Profit | 1.04 | 1.15 | 0.97 | 1 | 2.08 | 4.02 | Upgrade
|
| Selling, General & Admin | 3.79 | 3.98 | 4.3 | 4.05 | 4.05 | 3.7 | Upgrade
|
| Research & Development | 0.29 | 0.3 | 0.3 | 0.32 | 0.34 | 0.32 | Upgrade
|
| Operating Expenses | 4.08 | 4.28 | 4.6 | 4.37 | 4.39 | 4.02 | Upgrade
|
| Operating Income | -3.05 | -3.13 | -3.63 | -3.37 | -2.31 | 0 | Upgrade
|
| Interest Expense | -0.19 | -0.16 | -0.01 | -0.01 | -0 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | -0 | - | -0 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -3.24 | -3.29 | -3.65 | -3.38 | -2.32 | 0 | Upgrade
|
| Asset Writedown | -0.06 | -0.06 | -0.32 | -0.35 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.24 | - | - | Upgrade
|
| Pretax Income | -3.3 | -3.35 | -3.96 | -3.49 | -2.32 | 0 | Upgrade
|
| Net Income | -3.3 | -3.35 | -3.96 | -3.49 | -2.32 | 0 | Upgrade
|
| Net Income to Common | -3.3 | -3.35 | -3.96 | -3.49 | -2.32 | 0 | Upgrade
|
| Shares Outstanding (Basic) | 112 | 112 | 111 | 89 | 87 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 112 | 112 | 111 | 89 | 87 | 85 | Upgrade
|
| Shares Change (YoY) | 0.29% | 0.41% | 25.41% | 1.91% | 3.03% | 16.10% | Upgrade
|
| EPS (Basic) | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | Upgrade
|
| Free Cash Flow | -2.59 | -2.53 | -3.31 | -2.5 | -1.69 | 0.61 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 | 0.01 | Upgrade
|
| Gross Margin | 57.60% | 58.69% | 51.73% | 53.97% | 52.84% | 58.13% | Upgrade
|
| Operating Margin | -169.56% | -159.50% | -193.29% | -181.87% | -58.85% | 0.06% | Upgrade
|
| Profit Margin | -183.86% | -170.66% | -211.03% | -188.40% | -59.05% | 0.06% | Upgrade
|
| Free Cash Flow Margin | -144.35% | -128.94% | -176.40% | -134.86% | -42.98% | 8.83% | Upgrade
|
| EBITDA | -2.9 | -2.98 | -3.51 | -3.16 | -2.14 | 0.2 | Upgrade
|
| EBITDA Margin | -161.32% | -151.96% | -187.05% | -170.37% | -54.47% | 2.83% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.15 | 0.12 | 0.21 | 0.17 | 0.19 | Upgrade
|
| EBIT | -3.05 | -3.13 | -3.63 | -3.37 | -2.31 | 0 | Upgrade
|
| EBIT Margin | -169.56% | -159.50% | -193.29% | -181.87% | -58.85% | 0.06% | Upgrade
|
| Revenue as Reported | 1.8 | 1.96 | 1.88 | 1.85 | 3.93 | 6.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.